Merit Medical Systems, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; this is an annual filing, not a standalone fourth-quarter report. Merit develops and sells medical devices for interventional, diagnostic and therapeutic procedures. Its reportable segments are cardiovascular and endoscopy.
Financial performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $1.257 billion | $1.151 billion |
| Gross profit / margin | $583.9 million / 46.4% | $519.1 million / 45.1% |
| Operating income / margin | $123.9 million / 9.9% | $87.6 million / 7.6% |
| Net income | $94.4 million | $74.5 million |
| Diluted EPS | $1.62 | $1.29 |
| Cash from operating activities | $145.2 million | $114.3 million |
| Capital expenditures | $34.3 million | $45.0 million |
- Sales increased 9.2%. Cardiovascular sales rose 9.2% to $1.221 billion; endoscopy sales rose 12.4% to $36.8 million. U.S. sales grew 11.7% to $727.0 million; international sales grew 6.0% to $530.4 million.
- Gross margin improved primarily with higher sales, product mix and standard-cost changes, and lower freight costs; higher royalties and acquisition-related amortization partly offset those benefits. Operating expenses rose, including higher labor, variable compensation, R&D, regulatory and clinical-trial costs.
- Other expense increased to $11.9 million from $4.9 million, mainly from higher interest expense. The effective tax rate rose to 15.8% from 9.8%.
- Cash and cash equivalents were $587.0 million at year-end; cash, cash equivalents and restricted cash totaled $589.1 million. Inventory was $303.9 million, up from $266.0 million, reflecting safety stock and production-transfer planning.
Debt, liquidity and investment
- Outstanding debt principal was $846.6 million, including $747.5 million of 3.00% convertible senior notes due 2029 and $99.1 million of term loans. Balance-sheet long-term debt, net of issuance costs, was $823.0 million.
- The notes generated approximately $724.8 million of net proceeds before capped-call costs; Merit paid $66.5 million for capped calls. The credit agreement was amended in 2023 and is secured by substantially all company assets. Merit reported approximately $626 million of additional borrowing capacity, subject to leverage limits, and said it was in compliance with covenants.
- Investing cash outflow was $175.3 million, including $138.3 million for acquisitions. Merit expects 2024 property-and-equipment spending of approximately $50–$60 million. Management believes cash, operating cash flow and borrowing availability will fund planned operations for the next 12 months and foreseeable future.
Material changes, outlook and risks
- Merit completed acquisitions of AngioDynamics dialysis catheter and BioSentry assets and Bluegrass’s Surfacer access system in 2023. Acquired AngioDynamics products contributed approximately $14.4 million of 2023 sales.
- The company completed its three-year Foundations for Growth program and introduced Continued Growth Initiatives with multi-year targets through 2026; numerical targets are not provided in the supplied filing text.
- Management cited stronger-than-anticipated U.S. demand and better international trends, particularly in EMEA and rest-of-world markets. China’s volume-based procurement policy reduced prices and volumes in 2022 and 2023; management expects further negative effects in 2024.
- Key risks include supply-chain and input-cost pressures, pricing and reimbursement constraints, foreign-exchange exposure, regulatory approval and EU MDR compliance, product liability, cybersecurity, and competition. The filing also describes an ongoing SEC inquiry concerning the China subsidiary’s business activities; its scope, timing and outcome are uncertain.
- Merit remains subject to a five-year Corporate Integrity Agreement entered into in 2020 following a DOJ settlement; noncompliance could result in penalties or exclusion from federal healthcare programs. CEO Fred Lampropoulos is expected to retire at the end of FY2025, subject to succession planning.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Investor facts to verify
- How 2024 China VBP pricing and volume effects compare with management’s expectations, and whether growth outside China offsets them.
- Convertible-note and credit-agreement terms, covenant headroom, interest costs and the intended use and returns on financing proceeds.
- Acquisition performance, integration progress and the assumptions supporting acquired technology valuations and future amortization.
- Progress on the Wrapsody clinical trial and regulatory approvals, including EU MDR certification and any planned product discontinuations.
- Developments in the SEC inquiry and compliance with the Corporate Integrity Agreement.